Abstract library

162 results for "Serum amyloid A1".
#2173 Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: He Na
Authors: Na H, Qiyun T
#674 Serum miRNA Expression in Small Intestine Neuroendocrine Tumors and Biological Function of miR-196a in Neuroendocrine Tumor Cells
Introduction: MicroRNAs (miRNAs), post-transcriptional regulators, function either as tumor suppressors or oncogenes. We recently identified five upregulated and four downregulated miRNAs in small intestinal neuroendocrine tumor (SI-NET) tissue. We then started new analysis on body fluids to detect tumor signatures using patients’ serum.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Rakan Naboulsi
Authors: Naboulsi R, Li S C, Cui T, Öberg K, ...
#807 MicroRNA Expression in Serum of Small Intestine Neuroendocrine Tumor Patients and miR-196a Biological Function in Neuroendocrine Tumor Cells
Introduction: We have previously identified five upregulated and four downregulated miRNAs in small intestinal neuroendocrine tumor (SI-NET) tissue. We extended our analysis to serum samples of SI-NET patients to depict miRNAs functions.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Su-Chen Li
Authors: Li S C, Khan M S, Caplin M, Öberg K, ...
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#2144 Analysis of the Proteomics of Serum Circulating Exosomes in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms(GEP-NENs) are intractable, heterogeneous tumors, characterized by secreting serotonin metabolites or polypeptide hormones. There are currently little targets for the diagnosis and treatment of GEP-NENs. Serum circulating exosomes (scrExos) are extracellular vesicles secreted by all cells especially neuroendocrine cells to some extent, circulating in the blood with proteins and nucleic acids.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Bai Jian-An
Authors: Jian-An B, Qiyun T, Ye T, ...
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#1658 The Clinical Significance of Elevated Serum Procalcitonin in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Elevated serum procalcitonin (PCT) was reported in some patients with neuroendocrine neoplasms (NEN), but its clinical significance in gastroenteropancreatic NEN (GEP-NEN) was still unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Jie Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#585 Global microRNA profiling of small intestine neuroendocrine tumors (SI-NETs) and establishment of a method to study serum microRNA expression from the same tumors
Introduction: MicroRNAs (miRNAs) are important post-transcriptional regulatorsin biological processes and function either as tumor suppressors or oncogenes.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...
#623 Measurement of Serum Chromogranin A Level in 56 Patients with Neuroendocrine Tumors Using Immunoradiometric Assay
Introduction: More NETs have been diagnosed with the increasing awareness of the diseases, but few centers in China have introduced CgA testing as a tumor marker.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: professor Huangying Tan
Authors: Tan H, Jia L, ...
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico